BI 811283

Drug Profile

BI 811283

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 31 Aug 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Germany (IV)
  • 31 Aug 2015 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy) in Germany (IV)
  • 25 Nov 2011 Boehringer Ingelheim completes enrolment in its Phase-I/IIa trial for Acute myeloid leukaemia in Germany (NCT00632749)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top